Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$19.26M+93.22%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alison Moore
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 146
- Beta
- 2.39
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -4.74
Financials
Revenue
$19.26M+93.2%Net Income
$-8.13MEBITDA
$-5.64MFree Cash Flow
$-7.84M-285.9%EPS (diluted)
$-0.08Shares Outstanding (diluted)
107.26M+161.6%Operating Expenses
$22.68MCash & Debt
$72.66MReturn of Capital
$0.00Revenue by Segment (annual)
$70.39MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $70.39M | $-43.97M | $-0.50 |
| 2024 | $59.34M | $-65.28M | $-0.89 |
| 2023 | $70.14M | $-76.24M | $-1.12 |
| 2022 | $138.59M | $-33.59M | $-0.51 |
| 2021 | $104.75M | $-21.28M | $-0.33 |
| 2020 | $69.06M | $-24.01M | $-0.40 |
| 2019 | $68.46M | $-11.94M | $-0.21 |
| 2018 | $60.59M | $-10.88M | $-0.21 |
| 2017 | $50.02M | $-23.00M | $-0.50 |
| 2016 | $48.84M | $-8.56M | $-0.21 |
| 2015 | $41.80M | $-7.58M | $-0.19 |
| 2014 | $35.31M | $-19.07M | $-0.50 |
| 2013 | $31.92M | $-41.30M | $-1.08 |
| 2012 | $88.30M | $-30.86M | $-0.84 |
Valuation
CDXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·3d ago·Negative
Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Piper Sandler 38th Annual Healthcare Conference, being held December 1-3, 2026, in New York, New York.
View source ↗ - Newsglobenewswire.com·12d ago·Negative
Codexis Enters into $60 Million Term Loan Facility with Trinity Capital REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into a $60 million senior secured term loan agreement with Trinity Capital Inc. (NYSE: TRIN), a leading provider of flexible capital solutions for life sciences and healthcare industries.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy Data shared at TIDES Europe demonstrates consistent and robust platform performance while
View source ↗ - Newsglobenewswire.com·24d ago·Negative
Codexis to Report Third Quarter 2026 Financial Results on November 12 REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.
View source ↗ - Newsglobenewswire.com·87d ago·Negative
Codexis to Participate in Cantor Global Healthcare Conference 2026 REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.
View source ↗ - Newszacks.com·100d ago·Positive
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·103d ago·Negative
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
View source ↗ - Newsmarketbeat.com·103d ago·Negative
Codexis Q2 Earnings Call Highlights Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
View source ↗
Earnings
Wed, Mar 10(in 4 months)
Consensus estimate $-0.04 per share
Typical surprise +8.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.08 vs $-0.10beat
- Tue, Aug 11$-0.13 vs $-0.14beat
- Thu, May 7$-0.10 vs $-0.11beat
- Wed, Mar 11$0.11 vs $0.01beat
- Thu, Nov 6$-0.22 vs $-0.15miss
- Wed, Aug 13$-0.16 vs $-0.17beat
Estimates and results for CDXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CDXS officers and directors.
- Bought
- $9.4m
- Sold
- $5.7m
32 trades
31 trades
- Moore Alisonsold
- De Vre Raymondsold
- Erbez Georgiasold
- Moore Alisonsold
- De Vre Raymondsold
- Lutz Stefansold
- Lutz Stefansold
- Erbez Georgiasold
37 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lamar Seeligson Smithhouse · TX21 · disclosed May 8, 2018 (32d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
